ClinicalTrials.gg
CompletedNCT00504543AEB071Updated Nov 18, 2016

Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients

A Phase 2 interventional study of AEB071 and Certican in Kidney Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 26 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
311
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will assess safety and efficacy of AEB071 combined with everolimus in a CNI-free (calcineurin inhibitor) regimen in renal transplant recipients.

02

Conditions studied

  • Kidney Transplantation

Keywords

  • Kidney transplant, AEB071
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients 18 years or older
  • Recipients of first kidney transplant from a deceased or living not related donor

Exclusion criteria

Exclusion criteria

  • Need for medication prohibited in the study
  • Patients with heart disease (own or family history)
  • Patients or donor , (HBsAg) or (HCV) positive
  • Patients with high immunological risks
  • Patients with a history of cancer
  • Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
311 participants (actual)

Study arms

  • Active comparator
    Neoral

    Drug: Neoral

  • Active comparator
    AEB071 high dose with Cetican reduced dose

    Drug: AEB071 · Drug: Certican

  • Active comparator
    AEB071 low dose with Cetican standard dose

    Drug: AEB071 · Drug: Certican

Interventions

06

What researchers measure

Primary outcomes

  1. Primary efficacy failure, defined as a composite efficacy endpoint of treated biopsy proven acute rejection,(BPAR) graft loss, death or loss to follow-up, 3 months after transplantation.

    Time frame: 12 months

Secondary outcomes

  1. Primary efficacy failure endpoint,defined as a composite efficacy endpoint of treated(BPAR),graft loss, death or loss to follow-up of additional treatment regimen at Month 6; renal function at Month 3, Month 6 and Month 12 post transplant using GFR; PK

    Time frame: 12 months

07

Study locations

26 sites
  • Argentina
    Buenos Aires, 1107, Argentina
  • Novartis Investigative Site
    Buenos Aires, 1425, Argentina
  • Australia
    Sydney, 2050, Australia
  • Australia
    Sydney, 5011, Australia
  • Austria
    Innsbruck, 6020, Austria
  • Austria
    Wein, 1090, Austria
  • Belgium
    Gent, 9000, Belgium
  • Brazil
    Sao Paulo, 04038-002, Brazil
  • Novartis Investigative Site
    Bogota, Colombia
  • Novartis Investigative Site
    Cali, Colombia
  • Czech Republic
    Praha, 14021, Czech Republic
  • France
    Lille Cedex, 59037, France
  • France
    Toulouse, 31055, France
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Italy
    Milano, 20100, Italy
  • Italy
    Milano, 20122, Italy
  • Netherlands
    Rotterdam, 3000CA, Netherlands
  • Norway
    Oslo, 0027, Norway
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Banska Bystrica, 97517, Slovakia
  • Novartis Investigative Site
    Kosice, 04066, Slovakia
  • Spain
    Barcelona, 08024, Spain
  • Spain
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
  • Novartis Investigative Site
    Taipie, 10002, Taiwan
08

References and documents

Publications

  • Tedesco-Silva H, Kho MM, Hartmann A, Vitko S, Russ G, Rostaing L, Budde K, Campistol JM, Eris J, Krishnan I, Gopalakrishnan U, Klupp J. Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients. Am J Transplant. 2013 Jul;13(7):1757-68. doi: 10.1111/ajt.12255. Epub 2013 May 9. PubMed 23659755 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2007
First posted
Jul 20, 2007
Start
Jul 2007
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Last update
Nov 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00504543
Responsible party
Sponsor
First posted
Jul 20, 2007
Start date
Jul 2007
Primary completion
Apr 2011
Completion
Apr 2011
Last update
Nov 18, 2016

Study contacts

Novartis
study director · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sotrastaurin · Cyclosporine

Start the discussion